ArticleCureus2026
Effectiveness and Safety of Two Thrombopoietin Receptor Agonists: A Retrospective Cohort Study of Adults With Primary Immune Thrombocytopenia.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEvidence on the comparative effectiveness and safety of thrombopoietin receptor agonists (TPO-RAs) in adults with primary immune thrombocytopenia (ITP) is scarce. We conducted a retrospective cohort study at a Colombian university hospital to describe the effectiveness and safety of romiplostim (ROM) and eltrombopag (ELT) and to explore comparative outcomes between treatment groups. METHODOLOGY: A retrospective cohort study was conducted using medical records of adults with primary ITP treated at the Hospital Universitario Nacional de Colombia (Colombia National University Hospital) between 2016 and 2023. Effectiveness and safety outcomes are described, and the probability of platelet response was determined using Kaplan-Meier analysis.
resultsA total of 58 patients were included (63.8% women), with a mean age of 48 years. The median number of prior treatments was 3.00 (interquartile range (IQR), 3.00-4.00) for the ROM group and 2.00 (IQR, 2.00-3.00) for the ELT group (p < 0.001). The median time to achievement of the first platelet response was 37 days (95% confidence interval (CI), 19-61) in patients treated with ELT and 71 days (95% CI, 12-162) in those treated with ROM (p = 0.50). The proportion of patients achieving at least one platelet response during follow-up was 97.3% for ELT and 100% for ROM (p = 1.000). No statistically significant difference in the probability of achieving a platelet response was observed between treatment groups (log-rank p = 0.461). Thrombotic events and treatment-related adverse events were infrequent.
conclusionsIn this real-world retrospective study, no statistically significant differences were observed between ELT and ROM in time to platelet response or the probability of platelet response. Safety outcomes were infrequent in both groups. Patients treated with ROM had received more prior therapies and more frequently had undergone splenectomy, suggesting a population with more advanced disease at treatment initiation. These findings provide comparative real-world data from a Latin American cohort and should be interpreted as exploratory and hypothesis-generating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.